Kivexa (Abacavir, Lamivudine)

Both abacavir and lamivudine are nucleoside analogues that, after intracellular phosphorylation, mimic natural nucleotides. When incorporated by HIV reverse transcriptase into the growing viral DNA chain, they cause premature termination, thereby blocking viral replication.

The dosing regimen for Kivexa is determined by the prescribing clinician based on current HIV treatment guidelines, patient weight, renal function, and other individual factors. Patients should follow the exact dose and schedule provided by their healthcare professional.

Safety data for Kivexa in pregnancy and lactation are limited. Clinicians must weigh the potential benefits against possible risks and consider alternative regimens when appropriate. Breastfeeding decisions should be made in consultation with a qualified healthcare provider.

To request Kivexa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Kivexa combines two NRTIs in a single tablet, simplifying regimens compared with separate tablets such as abacavir + lamivudine + zidovudine. Compared with fixed‑dose combos like Truvada (tenofovir + emtricitabine), Kivexa lacks a tenofovir component, which may be advantageous for patients with renal concerns but offers a different resistance profile.

Kivexa tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the container tightly closed and out of reach of children.

Kivexa is taken orally as a tablet, usually once daily. It can be swallowed with or without food, but patients should follow any specific instructions from their prescriber regarding timing with meals.

The most serious adverse events include hypersensitivity reactions (fever, rash, organ involvement), severe liver injury, lactic acidosis, Stevens‑Johnson syndrome, and significant hematologic abnormalities such as neutropenia. Any of these symptoms require immediate medical attention.

Kivexa should be avoided in individuals with known hypersensitivity to abacavir, lamivudine, or any tablet components, and in patients who test positive for the HLA‑B*5701 allele due to a high risk of abacavir hypersensitivity. Severe hepatic impairment is also a contraindication.